By comparing the therapeutic in vivo efficacy of these three mAb variants, we conclude that h2G7 treatment alleviated APAP‐ALI through HMGB1 neutralization and has a prolonged therapeutic window, as compared to NAC treatment. The gene discussed is HMGB1; the disease is acute respiratory distress syndrome.